Bispecific therapeutics: a state-of-the-art review on the combination of immune checkpoint inhibition with costimulatory and non-checkpoint targeted therapy [0.03%]
免疫检查点抑制与协同刺激及非免疫检查点靶向治疗的联合疗法：综述
Samin Mortaheb,Parmida Sadat Pezeshki,Nima Rezaei
Samin Mortaheb
Introduction: Immune checkpoint inhibitors (ICIs) have revolutionized the field of cancer immunotherapy and have enhanced the survival of patients with malignant tumors. However, the overall efficacy of ICIs remains unsat...
Pooled safety analysis from the VOLTAIRE clinical trials of adalimumab-adbm and adalimumab reference product in patients with rheumatoid arthritis, Crohn's disease, and chronic plaque psoriasis [0.03%]
VOLTAIRE临床试验的阿达木单抗ABPCW和参照药在类风湿性关节炎、克罗恩病和慢性斑块型银屑病患者中的汇总安全性分析
Stanley Cohen,Shaun Bender,Amy Shaberman et al.
Stanley Cohen et al.
Objectives: This analysis reported the incidence of safety endpoints across five phase 3 randomized controlled clinical trials in patients with rheumatoid arthritis (RA), Crohn's disease (CD), and chronic plaque psoriasis...
Will zilebesiran, an RNA interference therapy, be effective, safe, and improve the treatment of hypertension? [0.03%]
泽雷布西兰（一种RNA干扰疗法）能否有效且安全地治疗高血压？
Sheila A Doggrell
Sheila A Doggrell
Introduction: Less than half of the subjects with hypertension have been diagnosed and treated, with only 21% having their blood pressure under control. Many of the subjects find it difficult to adhere to daily antihypert...
Nada Chaoul,Eleonora Lauricella,Andrea Giglio et al.
Nada Chaoul et al.
Introduction: Systemic treatment options for renal cell carcinoma (RCC) have expanded considerably in recent years, and both tyrosine kinase inhibitors and immune checkpoint inhibitors, alone or in combination, have enter...
Optimization of radiation target volume for locally advanced esophageal cancer in the immunotherapy era [0.03%]
免疫治疗时代局晚期食管癌放射目标体积的优化
Jian Zheng,Zhunhao Zheng,Tian Zhang et al.
Jian Zheng et al.
Introduction: Locally advanced esophageal cancer (EC) has poor prognosis. Preliminary clinical studies have demonstrated the synergistic efficacy of radiotherapy combined with immunotherapy in EC. Adjusting the radiothera...
An evaluation of ravulizumab for the treatment of neuromyelitis optica spectrum disorder [0.03%]
拉珠利单抗治疗视神经脊髓炎谱系障碍的效果评估
Denis T Balaban,Michael Levy,Ray Borrow et al.
Denis T Balaban et al.
Introduction: Following the CHAMPION-NMOSD trial, the FDA recently granted approval for ravulizumab, a humanized monoclonal antibody against complement C5 protein in AQP-4 seropositive neuromyelitis optica spectrum disord...
Recent developments and industry interest in gene therapy for Duchenne muscular dystrophy [0.03%]
杜氏肌营养不良症基因治疗的最新进展及行业兴趣
Hidenori Moriyama,Toshifumi Yokota
Hidenori Moriyama
Evaluation of orphan maintained biological medicinal products in the European Union between 2018 to 2023: a regulatory perspective [0.03%]
欧盟2018年至2023年孤儿维持生物药监管评估分析报告
Paolo Caferra,Thomas Fraisse,Maria Letizia Trincavelli et al.
Paolo Caferra et al.
Objectives: Orphan medicinal products (OMPs) authorized by the European Union (EU) benefit from market exclusivity, fee waivers, and national incentives. Maintaining orphan status during a marketing authorization applicat...
Stem cell therapy for type-2 diabetes: keeping the pedal to the metal to deliver translation to the clinic [0.03%]
干细胞治疗2型糖尿病：加速研发进程以实现临床转化
Ning Yang,LaTonya J Hickson,Lilach O Lerman
Ning Yang
A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer's disease [0.03%]
抗β淀粉样蛋白单克隆抗体治疗阿尔茨海默病有效性和安全性的系统评价研究
Akanksha Chhabra,Siddhant Solanki,Prithvi Saravanabawan et al.
Akanksha Chhabra et al.
Introduction: Alzheimer's disease can cause dementia through brain matter degradation. This study investigates the monoclonal antibody usage for AD treatment, following PRISMA 2020 guidelines, and aims to discern the mono...